Survey Demonstrates That Individuals With COPD Seek More Options To Reduce Risks Of Seasonal Respiratory Viral Infections
January 31, 2023
January 31, 2023
WASHINGTON, Jan. 31 -- The Chronic Obstructive Pulmonary Disease Foundation issued the following news release:
A survey conducted collaboratively by the COPD Foundation, a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, and ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylax . . .
A survey conducted collaboratively by the COPD Foundation, a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, and ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylax . . .